𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Radiotherapy plus razoxane for advanced limited extent carcinoma of the lung

✍ Scribed by Michael P. Corder; Hamed H. Tewfik; Gerald H. Clamon; Charles E. Platz; J. Thompson Leimert; Kenneth D. Herbst; John E. Byfield

Publisher
John Wiley and Sons
Year
1984
Tongue
English
Weight
438 KB
Volume
53
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Intraoperative radiotherapy for advanced
Intraoperative radiotherapy for advanced carcinoma of the pancreas
✍ Akira Nishimura; Masao Nakano; Hiroshi Otsu; Kikuo Nakano; Koyo Iida; Suoh Sakat πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 1012 KB

A detailed retrospective analysis of the efficacy of intraoperative radiotherapy (IOR) in advanced carcinoma of the pancreas is presented. During a 10-year period from 1973 through 1982, 70 patients with advanced carcinoma of the pancreas were treated by multimodal methods, separate or combined ther

Combination radiotherapy and chemotherap
Combination radiotherapy and chemotherapy for small cell carcinoma of the lung
✍ Goldberg, R. S. ;Joss, R. A. ;Bedwinek, J. ;Yates, J. W. ;Krakoff, I. H. πŸ“‚ Article πŸ“… 1979 πŸ› John Wiley and Sons 🌐 English βš– 319 KB

Twenty previously untreated patients with small cell carcinoma of the lung were treated with cyclophosphamide, 400 mg/m2 and Adriamycin, 40 mg/m2 IV on day 1, followed by cytosine arabinoside, 20 mg/m2, every 12 hours subcutaneously on days 5--9; this regimen was repeated every 28 days. On days 14--

A phase II study of weekly docetaxel plu
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma
✍ Ji-Youn Han; Dae Ho Lee; Hae Young Kim; Eun Kyung Hong; Sung Min Yoon; Jong Ho C πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Docetaxel is an active agent in advanced nonsmall‐cell lung carcinoma (NSCLC) and demonstrates preclinical and clinical synergism with capecitabine. We conducted the current Phase II study to evaluate the efficacy and safety of the docetaxel/capecitabine combination in ch